Portugal: Will the Life Science Sector See Upswing Amid Funding Worries?

Why It Matters

A stronger funding pipeline could unlock Portugal’s high‑skill talent and position the nation as a cost‑effective gateway to European biotech markets, attracting global investors and accelerating drug development timelines.

Key Takeaways

• Life sciences added $34.4bn gross value added in 2024
• First dedicated biotech VC, Biovance Capital, launched in Lisbon
• Gene‑therapy centre secured $44m European funding
• LXbio to release phase‑2 data on phage therapy soon
• Funding scarcity drives Portuguese innovators to seek overseas partners

Pulse Analysis

Portugal’s biotech landscape is evolving from a modest, research‑heavy model to a more commercialized ecosystem. The sector’s $34.4 billion contribution to GDP reflects a maturing cluster of firms, university spin‑outs, and specialized parks such as Biocant, which now hosts nearly 25 startups. Hosting BIO‑Europe Spring amplified international awareness, positioning Lisbon as a strategic hub for collaborations and showcasing high‑impact deals like BioNTech’s acquisition of CellmAbs, the nation’s first billion‑dollar transaction in life sciences.

Despite these advances, capital scarcity remains the primary bottleneck. Historically, Portuguese biotech lacked dedicated venture capital, with only three years since the inception of Biovance Capital, the country’s inaugural life‑science‑focused fund. Researchers and founders often need multi‑million‑euro investments to move from proof‑of‑concept to market, prompting talent migration to better‑funded ecosystems. Recent policy moves—such as a €145 million ($168 million) research grant program, expanded PhD scholarships, and alignment with the EU Clinical Trials Regulation—aim to create a more supportive financing environment and streamline drug‑development pipelines.

The pipeline of innovation, however, shows resilience. A €38 million ($44 million) gene‑therapy centre and the pioneering Multidisciplinary Institute of Ageing illustrate strong public‑private research synergy. Meanwhile, LXbio’s upcoming phase‑2 results on a phage‑based therapy for diabetic foot infections could validate Portugal’s capacity for breakthrough therapeutics. If funding mechanisms mature and visibility from events like BIO‑Europe Spring translates into sustained investment, Portugal could leverage its skilled workforce, lower cost base, and strategic location to become a competitive gateway for biotech firms targeting the broader European market.